📰 Valuating News
Page 19 - Valuating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valuating. Real-time updates on events, politics, business and more.
August 19, 2021
- Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone - - Data support the use of toripalimab with chemotherapy as first-line
August 18, 2021
Central African Gold Inc. is pleased to announce the Corporation is evaluating the feasibility of implementing a carbon credit revenue stream on its vast land position in the Democratic Republic... | August 19, 2021
August 16, 2021
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant... | August 18, 2021
June 26, 2021
Biden Admin Is Paying Contractors Not to Build Wall But to Sit and Watch Piles of Steal Beams and Sections of Wall from Being Stolen By Jim Hoft
June 10, 2021
THR-687 is a potent pan-RGD integrin antagonistholding potential as next generation first line therapy for DME Leuven, BE, Boston, MA, US - June 10, 2021 - 07.00 AM CET - Oxurion
June 1, 2021
Trial to evaluate safety, immunogenicity of various vaccine booster regimens.
May 28, 2021
Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept
May 27, 2021
This clinical trial will be sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics. The study will explorethe strategy
May 27, 2021
(0) -- Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with KRYSTEXXA monotherapy. For people with chronic gout refractory ...
April 27, 2021
SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-ocular in Dry Eye Disease ProGIFT is a 3 arms, multicenter, randomized, double-masked clinical trial in Italy. CATANIA, Italy, April 27, 2021 /PRNewswire/ -- SIFI announced today the enrollment of the first patients in the ProGIFT trial (NCT04645446), which aims at evaluating the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with Dry Eye Disease (DED). ProGIFT (NCT04645446) is a multicenter, ran...